Text Size

UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

This study has been completed.
Sponsor:
Information provided by:
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00577512
First received: December 18, 2007
Last updated: April 19, 2011
Last verified: April 2011
History of Changes
Results First Received: April 19, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Intervention: Drug: DTPACE

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
HD DTPACE
  1. High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored
  2. High dose DTPACE and stem cell re-infusion
  3. VTD Maintenance therapy

Participant Flow:   Overall Study
    HD DTPACE  
STARTED     4  
COMPLETED     0  
NOT COMPLETED     4  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
HD DTPACE
  1. High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored
  2. High dose DTPACE and stem cell re-infusion
  3. VTD Maintenance therapy

Baseline Measures
    HD DTPACE  
Number of Participants  
[units: participants]
 		  4  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     4  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation 		  54.3  ± 6.24  
Gender  
[units: participants]
 		 
Female     2  
Male     2  
Region of Enrollment  
[units: participants]
 		 
United States     4  



  Outcome Measures

1.  Primary:   Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer.   [ Time Frame: 12 months ]
  Show Outcome Measure 1

2.  Secondary:   In Subjects Achieving a Response, to Find Out How Long the Response Will Last.   [ Time Frame: 12 months ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Nathan M. Petty
Organization: University of Arkansas for Medical Sciences, Myeloma Institute
phone: 501-526-6990 ext 2461
e-mail: pettynathanm@uams.edu


No publications provided


Responsible Party: Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences
ClinicalTrials.gov Identifier: NCT00577512     History of Changes
Other Study ID Numbers: 2006-32
Study First Received: December 18, 2007
Results First Received: April 19, 2011
Last Updated: April 19, 2011
Health Authority: United States: Institutional Review Board